EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo

Jin,Yiting; Zhang,Wei; Wang,Hongying; Zhang,Zijing; Chu,Chengyu; Liu,Xiuping; Zou,Qiang

doi:10.3892/or.2015.4444

February-2016 Volume 35 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2016 Volume 35 Issue 2

Full Size Image

Article

EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo

Authors:
- Yiting Jin
- Wei Zhang
- Hongying Wang
- Zijing Zhang
- Chengyu Chu
- Xiuping Liu
- Qiang Zou
View Affiliations / Copyright

Affiliations: Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200240, P.R. China, Department of Pathology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, P.R. China
Pages: 771-778
|
Published online on: November 25, 2015

https://doi.org/10.3892/or.2015.4444
Expand metrics +

Abstract

Multidrug resistance (MDR) induced by chemotherapy in breast cancer frequently leads to tumor invasion, metastasis and poor clinical outcome. We preliminarily found that the epidermal growth factor receptor (EGFR) is involved in enhancing the malignant potential of MDR breast cancer cells, but the mechanism remains unclear. In the present study, we demonstrated in vitro and in vivo that EGFR/HER2 promote the invasive and metastatic abilities of MDR breast cancer. More importantly, a new function of EGFR/HER2 inhibitors was revealed for the first time, which could improve the treatment efficacy of breast cancer by reversing the MDR process rather than by inhibiting tumor growth. Firstly, using quantitative real‑time PCR and western blot analysis, we found that overexpression of EGFR/HER2 in MCF7/Adr cells upregulated CD147 and MMP2/9 at both the transcription and protein expression levels, which promoted tumor cell migration, as determined using an in vitro invasion assay. Secondly, the upregulated levels of CD147 and MMP2/9 were decreased when EGFR/HER2 activity was inhibited, and therefore tumor invasion was also significantly inhibited. These phenomena were also demonstrated in nude mouse assays. Additionally, in MDR breast cancer patients, we found that overexpression of EGFR and P‑gp levels led to shorter overall survival (OS) and disease‑free survival (DFS) by IHC assays and Kaplan‑Meier survival analysis. In conclusion, EGFR/HER2 play a crucial role in enhancing CD147 and MMP expression to establish favorable conditions for invasion/metastasis in MDR breast cancer. The scope of application of EGFR/HER2 inhibitors may be expanded in EGFR/HER2‑positive patients. We suggest that MDR breast cancer patients may benefit from novel therapies targeting EGFR/HER2.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Shustik C, Dalton W and Gros P: P-glycoprotein-mediated multidrug resistance in tumor cells: Biochemistry, clinical relevance and modulation. Mol Aspects Med. 16:1–78. 1995. View Article : Google Scholar : PubMed/NCBI
3	Li QQ, Wang WJ, Xu JD, Cao XX, Chen Q, Yang JM and Xu ZD: Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci. 98:1064–1069. 2007. View Article : Google Scholar : PubMed/NCBI
4	Li QQ, Wang WJ, Xu JD, Cao XX, Chen Q, Yang JM and Xu ZD: Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci. 98:1767–1774. 2007. View Article : Google Scholar : PubMed/NCBI
5	Araújo AP, Catarino R, Ribeiro R, Pereira D, Pinto D and Medeiros R: Epidermal growth factor genetic variation associated with advanced cervical cancer in younger women. Am J Clin Oncol. 35:247–250. 2012. View Article : Google Scholar
6	Xu JW, Li QQ, Tao LL, Cheng YY, Yu J, Chen Q, Liu XP and Xu ZD: Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells. Int J Oncol. 39:1501–1509. 2011.PubMed/NCBI
7	Gazdar AF: Epidermal growth factor receptor inhibition in lung cancer: The evolving role of individualized therapy. Cancer Metastasis Rev. 29:37–48. 2010. View Article : Google Scholar : PubMed/NCBI
8	Horii R, Honma N, Ogiya A, Kozuka Y, Fukuda T, Yoshida M, Ohsumi S and Mukai H; Japanese Breast Cancer Society: The Japanese Breast Cancer Society Clinical Practice Guideline for pathological diagnosis of breast cancer. Breast Cancer. 22:59–65. 2015. View Article : Google Scholar
9	Han HJ, Russo J, Kohwi Y and Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 452:187–193. 2008. View Article : Google Scholar : PubMed/NCBI
10	DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
11	Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: From genomics to mechanism. Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
12	Chiou JF, Liang JA, Hsu WH, Wang JJ, Ho ST and Kao A: Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung. 181:267–273. 2003. View Article : Google Scholar
13	Szachowicz-Petelska B, Figaszewski Z and Lewandowski W: Mechanisms of transport across cell membranes of complexes contained in antitumour drugs. Int J Pharm. 222:169–182. 2001. View Article : Google Scholar : PubMed/NCBI
14	Yang JM, Yang GY, Medina DJ, Vassil AD, Liao J and Hait WN: Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. Biochem Biophys Res Commun. 266:167–173. 1999. View Article : Google Scholar : PubMed/NCBI
15	Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC and Elledge RM: Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer. 116:1234–1242. 2010. View Article : Google Scholar : PubMed/NCBI
16	Menashi S, Serova M, Ma L, Vignot S, Mourah S and Calvo F: Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res. 63:7575–7580. 2003.PubMed/NCBI